Molluscum Contagiosum Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novan, Inc., Veloce Biopharma, Abbott, Medtronic, Gurina Foundation

Posted on
by

Molluscum Contagiosum Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novan, Inc., Veloce Biopharma, Abbott, Medtronic, Gurina Foundation
“Molluscum Contagiosum Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Molluscum Contagiosum, historical and forecasted epidemiology as well as the Molluscum Contagiosum market trends in the 7MM.

DelveInsight’s “Molluscum Contagiosum Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Molluscum Contagiosum, historical and forecasted epidemiology as well as the Molluscum Contagiosum market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Molluscum Contagiosum market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Molluscum Contagiosum Market Forecast

 

Some of the key facts of the Molluscum Contagiosum Market Report: 

  • The Molluscum Contagiosum market size wad valued approximately USD 2 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The US had the highest number of Molluscum Contagiosum (MC) cases overall in 2021 with around 6,250,000 cases, and Spain had the lowest number with about 680,000 cases
  • Based on overall prevalence and cases specific to particular genders, Molluscum Contagiosum (MC) epidemiology was divided
  • In 2021, France had the majority of Molluscum Contagiosum (MC) cases among the EU5 nations (about 1.3 million cases)
  • Key Molluscum Contagiosum Companies: Competition Deep Dive, Novan, Inc., Veloce Biopharma, Gurina Foundation, Azafaros, Polaryx Therapeutics, Abbott, Medtronic, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, and others
  • Key Molluscum Contagiosum Therapies: VP-102, SB206, VB4-245, SB206, Picato, and others 
  • The Molluscum Contagiosum market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Molluscum Contagiosum pipeline products will significantly revolutionize the Molluscum Contagiosum market dynamics.

 

Molluscum Contagiosum Overview

Water warts, also known as Molluscum Contagiosum, are a frequent superficial skin illness brought on by the poxvirus. School-age children, sexually active young adults, and those with impaired immune systems are the main populations it affects.

 

Get a Free sample for the Molluscum Contagiosum Market Report 

https://www.delveinsight.com/report-store/molluscum-contagiosum-mc-market

 

Molluscum Contagiosum Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Molluscum Contagiosum Epidemiology Segmentation:

The Molluscum Contagiosum market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Molluscum Contagiosum
  • Prevalent Cases of Molluscum Contagiosum by severity
  • Gender-specific Prevalence of Molluscum Contagiosum
  • Diagnosed Cases of Episodic and Chronic Molluscum Contagiosum

 

Download the report to understand which factors are driving Molluscum Contagiosum epidemiology trends @ Molluscum Contagiosum Epidemiology Forecast

 

Molluscum Contagiosum Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Molluscum Contagiosum market or expected to get launched during the study period. The analysis covers Molluscum Contagiosum market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Molluscum Contagiosum Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Molluscum Contagiosum Therapies and Key Companies

  • VP-102: Verrica Pharma
  • SB206: Novan/Ligand Pharma
  • VB4-245: Veloce Biopharma
  • SB206: Novan, Inc.
  • Picato: LEO Pharma

 

Discover more about therapies set to grab major Molluscum Contagiosum market share @ Molluscum Contagiosum Treatment Market

 

Molluscum Contagiosum Market Strengths

  • The expected launch of newly approved therapies, VP-102 and SB206, is likely to spur market growth in the near future. These might lead to a revolutionary class of topical therapies (drug-device combo) that can offer a safe and effective alternative to aspecific treatments offered to MC patients
  • Increasing prevalence of the disease
  • Increasing demand for therapy with ease of administration and a longer time of action is likely to boost market uptake of new therapies.
  • Molluscum contagiosum is a viral infection estimated to increase in adults as the number of immune-compromised individuals’ increases.

 

Molluscum Contagiosum Market Opportunities

  • Despite a huge disease burden, there is a lack of approved therapies to treat molluscum contagiosum. 
  • Introduction of consistent and precise application method containing a controlled formulation with a proven dosing schedule, with testing completed in large populations of patients with molluscum
  • Refined and advanced clinical trial design.
  • Current methods of treatment have significant limitations, including pain, scarring, and unproven efficacy, and many are unsuitable for use in children

 

Scope of the Molluscum Contagiosum Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Molluscum Contagiosum Companies: Competition Deep Dive, Novan, Inc., Veloce Biopharma, Gurina Foundation, Azafaros, Polaryx Therapeutics, Abbott Medtronic, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, and others
  • Key Molluscum Contagiosum Therapies: VP-102, SB206, VB4-245, SB206, Picato, and others
  • Molluscum Contagiosum Therapeutic Assessment: Molluscum Contagiosum current marketed and Molluscum Contagiosum emerging therapies
  • Molluscum Contagiosum Market Dynamics: Molluscum Contagiosum market drivers and Molluscum Contagiosum market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Molluscum Contagiosum Unmet Needs, KOL’s views, Analyst’s views, Molluscum Contagiosum Market Access and Reimbursement 

 

To know more about Molluscum Contagiosum companies working in the treatment market, visit @ Molluscum Contagiosum Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Molluscum Contagiosum Market Report Introduction

2. Executive Summary for Molluscum Contagiosum

3. SWOT analysis of Molluscum Contagiosum

4. Molluscum Contagiosum Patient Share (%) Overview at a Glance

5. Molluscum Contagiosum Market Overview at a Glance

6. Molluscum Contagiosum Disease Background and Overview

7. Molluscum Contagiosum Epidemiology and Patient Population

8. Country-Specific Patient Population of Molluscum Contagiosum 

9. Molluscum Contagiosum Current Treatment and Medical Practices

10. Molluscum Contagiosum Unmet Needs

11. Molluscum Contagiosum Emerging Therapies

12. Molluscum Contagiosum Market Outlook

13. Country-Wise Molluscum Contagiosum Market Analysis (2019–2032)

14. Molluscum Contagiosum Market Access and Reimbursement of Therapies

15. Molluscum Contagiosum Market Drivers

16. Molluscum Contagiosum Market Barriers

17.  Molluscum Contagiosum Appendix

18. Molluscum Contagiosum Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/